Login
Voyager Therapeutics, Inc. logo

Voyager Therapeutics, Inc.

voyagertherapeutics.com

What Do They Do?

Develops gene therapies, antibodies and non-viral delivery platforms for neurological diseases, and licenses capsids and drug programs to pharmaceutical partners.

How Do They Make Money?

Pharmaceutical partners pay for licenses or options to license drug candidates and for research and development work. Agreements can bring upfront fees, research-cost reimbursements, option and milestone payments, and royalties on licensed-product sales; research-work payments accrue as work is carried out, while royalties are tied to sales.

FY2025 revenue

Who Are Their Customers?

Pharmaceutical companies work with Voyager through licensing and collaboration agreements covering capsids, drug programs and research and development services.

Do Revenues Turn Into Profits?

No. It lost $119.7M in FY2025.

Operating income, FY2025
−327% of revenue
▼ −58% (Loss) vs FY2024 (−$83.3M, −104%)
Net income, FY2025
−297% of revenue
▼ −84% (Loss) vs FY2024 (−$65M, −81%)
Free cash flow, FY2025
−335% of revenue
▼ −617% (Loss) vs FY2024 (−$18.8M, −24%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +11% (Loss)
vs −$27.9M in Q3 FY2025
  • Apr 21, 2026 Chief financial officer resigned Robin Swartz was appointed principal financial officer and treasurer effective with the transition.

Flat. Revenue was $40.4M in FY2025, about the same as the $37.4M of FY2021.

Proprietary pipeline focus The earlier prioritized proprietary pipeline paired an ALS gene therapy with an Alzheimer’s antibody; the latest centers the proprietary pipeline on Alzheimer’s tau programs and says investment in APOE gene therapy is paused.

Who Do They Compete With?

Competes with Lundbeck, Merck &, Teijin, Eisai, Janssen Pharmaceuticals, UCB, Bristol-Myers Squibb, Prothena, Ionis Pharmaceuticals, Biogen, Dewpoint Therapeutics, WaveBreak Therapeutics, Molefy Pharma, 4D Molecular Therapeutics, Affinia Therapeutics, Apertura Gene Therapy, Capsida Biotherapeutics, Capsigen, Dyno Therapeutics, and Sangamo Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support